Enveda Biosciences Raises $51M in Series A Financing finsmes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finsmes.com Daily Mail and Mail on Sunday newspapers.
Two Sigma Ventures, and others. This round brings Socure’s total funding to $196 million, following a recent $35 million investment less than six months ago led by Sorenson Ventures.
The new financing will support Socure’s expansion across every consumer-facing vertical including online gaming, healthcare, telco, e-commerce, and on-demand services. Proceeds from the round will also accelerate product innovation as the company’s patent portfolio grows and the company continues to attract top talent.
Amit Jhawar, partner at Accel and former general manager of Venmo, will join the board of directors at Socure.
The tremendous growth in the digital identity market is part of the macro trend of businesses migrating towards digital-first online services, commerce, and transactions, including for those services once defined by physical interaction and exchange. According to
Published: May 11, 2021 By Heather McKenzie
Appia co-founder and chief executive officer, JJ Kang/Photo Courtesy of Appia Bio
Backed by $52 million in Series A financing led by 8VC and named after a feat of engineering in ancient Rome, Appia Bio jumped into the cell therapy fray this morning with a promising scalable technology platform.
“The company is named after the Aqua Appia, which is the first Roman aqueduct. It was kind of a feat of engineering and it brought water to a lot more people, and that thematically connects well. We want to engineer these cells and provide a broader reach for cell therapy through allogeneic off-the-shelf,” said Appia co-founder and chief executive officer, JJ Kang, Ph.D.
Appia Bio Launches With $52 Million Series A Financing and Establishes Scientific Advisory Board
Proceeds will be used to progress stem cell derived CAR-engineered invariant natural killer T cells (CAR-iNKT) to the clinic in hematological and solid tumor indications
News provided by
Share this article
Share this article
LOS ANGELES, May 11, 2021 /PRNewswire/ Appia Bio, Inc., an early stage biotechnology company developing engineered allogeneic cell therapies from hematopoietic stem cells (HSCs) for cancer patients, today announced its launch from stealth backed by $52 million Series A financing led by 8VC. Other investors included Two Sigma Ventures, among others, and participation from seed investors Sherpa Healthcare Partners and Freeflow Ventures.